Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

Table 6 Relationship between change in TSQM and change in CAMPHOR QoL score

Predictor	Model R ²	Standardized β ± SE	p
Unadjusted Model
Effectiveness	0.13	−0.07 ± 0.02	0.002
Side effects	<0.01	−0.01 ± 0.02	0.81
Convenience	0.09	−0.05 ± 0.02	0.008
Global satisfaction	0.06	−0.05 ± 0.02	0.03
Adjusted Model
Effectiveness	0.12	−0.07 ± 0.02	0.002
Side effects	<0.01	−0.02 ± 0.03	0.50
Convenience	0.08	−0.05 ± 0.02	0.01
Global satisfaction	0.03	−0.04 ± 0.02	0.05

Adjusted model includes age, sex, race, etiology of PAH, WHO functional class, and type of background therapy.

ISSN: 1477-7525